In the latest move to advance regulatory reliance in Brazil, the country’s medicines regulator, Anvisa, has approved new guidance setting out criteria for making use of pre- and post-market drug evaluations carried out by the foreign authorities it deems to be “equivalent” regulatory bodies.
Brazil Issues Guidance On Regulatory Reliance & Equivalent Authorities
Mexico and Brazil set sights on GMP convergence
Brazilian regulator Anvisa is relying on the decisions of its foreign counterparts as a means of ensuring more quality medicines are made available in the country.
